Answers are grounded in this paper and cite their sources.
Dear Sir, A 23-year-old woman presented with lower abdominal pain at 27 weeks of gestation. She was gravida II with previous history of a cesarean delivery. She appeared stressed and an abdominal examination showed a single, longitudinal lie fetus with palpable uterine contraction. Speculum examination showed minimal bleeding. The impression acquired was preterm labor with an abruption of placenta. She was afebrile and her hemoglobin concentration was 10.1 g/dL. The neonatal intensive care unit was informed and an emergency cesarean delivery was planned. The blood bank was requested to process crossmatch for two units of packed red blood cells. The blood bank informed the obstetrics team that the patient had anti-e and anti-C alloantibodies and that crossmatched compatible blood was difficult to find. During cesarean section, the uterus showed ecchymosis and a placental clot about 200 mL noted. The patient continued to bleed with relaxation of her uterus in between. The patient's blood was noticed to be thinned without significant clotting. Clinically, disseminated intravascular coagulation was imminent, the patient's platelet count dropped to 41 × 109/L (from 123 × 109/L preoperatively) and her hemoglobin concentration was 5.5 g/dL. Two units of compatible blood, six units of fresh-frozen plasma, six units of cryoprecipitate and a dose of apheresis platelets were transfused. Because of persistent bleeding and a life-threatening condition, the decision to administer a single dose of 2.4 mg recombinant activated factor VII (rFVIIa) was taken. Both bleeding and oozing reduced significantly soon after the administration of rFVIIa. The patient remained stable after the surgery and was subsequently discharged without any complications. Postpartum hemorrhage (PPH) is one of the most important causes of massive obstetrical hemorrhage and the leading cause of maternal mortality worldwide. The leading cause of PPH is uterine atony, which accounts for at least 50% of all cases. Other risk factors include placental abnormalities (placenta previa, placenta abruptio, placenta accrete), previous cesarean section and multiparity. Placental abruption occurs in 1% of pregnancies worldwide with a fetal mortality rate of 20–40% depending on the degree of separation. Placental abruption is also a significant contributor to maternal mortality.1 The treatment of life-threatening PPH still remains challenging. The first-line standard treatment includes uterotonic drugs and replacement-transfusion therapy to control blood loss. Surgical interventions such as hysterectomy or ligation of the internal iliac arteries bilaterally may be required to control the bleeding. Some of these patients can end up with massive transfusion and may use several units of red blood cells, fresh-frozen plasma and platelets. Many of these patients can present with urgency to proceed to cesarean section. Factor VII, a vitamin K-dependent glycoprotein, is a serine protease that is converted by limited proteolysis into FVIIa, the enzymatically active form. FVIIa binds to tissue factor (TF), which activates the extrinsic coagulation pathway. Recombinant FVIIa (rFVIIa; NovoSeven, Novo Nordisk A/S, Bagsvaerd, Denmark) was developed initially for treatment of bleeding in hemophilia A patients with inhibitors.2 Under normal physiologic concentrations, rFVIIa induces hemostasis by binding to exposed TF at the site of endothelial injury to form a complex that activates FX, thereby producing thrombin. At pharmacologic doses, rFVIIa binds weakly to activated platelets independent of TF to activate FX and enhance thrombin generation.3 It has also been successfully used in nonhemophiliac patients with acquired antibodies against FVIII, congenital FVII deficiency, uncontrolled bleeding, thrombocytopenia and functional platelet defects.4,5 The first case report of successful treatment of intractable obstetric hemorrhage in a woman without hemophilia using rFVIIa was published by Moscardóet al. who reported that rFVIIa successfully controlled life-threatening PPH after cesarean section in a woman who developed severe disseminated intravascular coagulation, liver dysfunction and real failure.6 The use of rFVIIa in obstetric and gynecological hemorrhage was recently reviewed by Franchini et al.7,8 The blood transfusion service is confronted with a dilemma when blood and blood products compatible with the patient's blood type are in short supply. The situation may become more complex if the blood bank encounters antibodies against common antigen/antigens and serologically compatible blood is not available immediately. This is exactly what happened in the case of our patient. It is also important to emphasize that not all hospitals worldwide have access to a facility within a reasonable distance for rare donor registry or a central or regional blood bank from where compatible blood products can be obtained in timely manner. The urgent, critical need to control bleeding and the difficulties in obtaining compatible blood products may be the major contributors to the maternal mortality associated with PPH. In the present case, although it is difficult to appreciate the exact relationship, it was obvious to the team that the administration of rFVIIa was related to cessation of bleeding and finally led to the positive outcome. Although rFVIIa appears to be relatively safe, concerns about potential side effects have been raised and, therefore, would lead to a cautious approach in the use of this product for off-label indications. Considering the fact that rFVIIa can be effective in cases of life-threatening bleeding when all other therapies have failed, the apparent low incidence of thrombotic adverse effects seems justifiably acceptable. Our case presents a unique scenario and we believe that rFVIIa can be life-saving in patients with severe gynecological hemorrhage when compatible blood is unavailable or scarce. Early use of rFVIIa in PPH may reduce bleeding-related mortality and transfusion-related morbidity. As a concluding remark, we suggest that a strong communication between the patient's physician and the hematologist or the transfusion service physician (for institutions where rFVIIa is available through the transfusion service) is key to judicious and purposeful use of rFVIIa. We thank Zehra Farzal for her technical assistance.
No takes yet. Share an insight, caveat, or question.
Anwar et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: